|
Name |
(R)-5-phosphonatomevalonate(3-)
|
Molecular Formula | C6H10O7P-3 | |
IUPAC Name* |
(3R)-3-hydroxy-3-methyl-5-phosphonatooxypentanoate
|
|
SMILES |
C[C@@](CCOP(=O)([O-])[O-])(CC(=O)[O-])O
|
|
InChI |
InChI=1S/C6H13O7P/c1-6(9,4-5(7)8)2-3-13-14(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H2,10,11,12)/p-3/t6-/m1/s1
|
|
InChIKey |
OKZYCXHTTZZYSK-ZCFIWIBFSA-K
|
|
Synonyms |
(R)-5-phosphonatomevalonate(3-); 73566-35-5; (R)-5-phosphonatomevalonate; (R)-mevalonate 5-phosphate; CHEBI:58146; DTXSID30994347; (R)-5-phosphonatomevalonate trianion; 3-Hydroxy-3-methyl-5-(phosphonatooxy)pentanoate; (3R)-3-hydroxy-3-methyl-5-phosphonatooxypentanoate; (3R)-3-hydroxy-3-methyl-5-(phosphonatooxy)pentanoate; Q27125216
|
|
CAS | 73566-35-5 | |
PubChem CID | 25244548 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 225.11 | ALogp: | -1.6 |
HBD: | 1 | HBA: | 7 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 133.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 14 | QED Weighted: | 0.501 |
Caco-2 Permeability: | -5.926 | MDCK Permeability: | 0.00099117 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.607 | 20% Bioavailability (F20%): | 0.905 |
30% Bioavailability (F30%): | 0.978 |
Blood-Brain-Barrier Penetration (BBB): | 0.647 | Plasma Protein Binding (PPB): | 9.71% |
Volume Distribution (VD): | 0.262 | Fu: | 75.54% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.091 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.044 |
CYP2C9-inhibitor: | 0.007 | CYP2C9-substrate: | 0.918 |
CYP2D6-inhibitor: | 0.026 | CYP2D6-substrate: | 0.107 |
CYP3A4-inhibitor: | 0.008 | CYP3A4-substrate: | 0.011 |
Clearance (CL): | 1.6 | Half-life (T1/2): | 0.761 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.08 |
Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.019 |
Rat Oral Acute Toxicity: | 0 | Maximum Recommended Daily Dose: | 0.572 |
Skin Sensitization: | 0.334 | Carcinogencity: | 0.041 |
Eye Corrosion: | 0.977 | Eye Irritation: | 0.989 |
Respiratory Toxicity: | 0.171 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001610 | 0.500 | D0QC5D | 0.308 | ||||
ENC001759 | 0.378 | D01EKQ | 0.308 | ||||
ENC002634 | 0.296 | D04CJL | 0.308 | ||||
ENC002702 | 0.274 | D07QPM | 0.296 | ||||
ENC001900 | 0.220 | D0Q4EW | 0.296 | ||||
ENC001187 | 0.220 | D0OT0O | 0.293 | ||||
ENC000643 | 0.217 | D00XUN | 0.265 | ||||
ENC000377 | 0.205 | D08VYC | 0.216 | ||||
ENC001245 | 0.203 | D03RCJ | 0.213 | ||||
ENC000719 | 0.200 | D02CYR | 0.211 |